China’s BeiGene now has $5B+ cash in its coffers. How’s the Amgen-partnered biotech going to spend it?

When Amgen wagered $2.7 billion to grab a 20.5% stake in BeiGene late last year, execs saw themselves buying into a “world-class operation” that would help them tap into the world’s most populous country and a growing biopharma powerhouse. It turns out they were just getting started. Over the weekend,…